No Data
No Data
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ): Indirect controlling shareholder Chengdu Yuanhong completed the shareholding of 9.14 million shares.
On July 19th, GeLonghui reported that Chengdu Huasun Technology Group Inc., Ltd. (stock code: 000790.SZ) announced that the company has recently received a notice from Chengdu Yuanhong, its indirectly-controlled shareholder, regarding the completion of the shareholding plan of Chengdu Huasun Technology Group Inc., Ltd. As of the date of this announcement, the shareholding plan has been completed, and Chengdu Yuanhong has accumulated 9.14 million shares of the company through the Shenzhen Stock Exchange trading system in a centralized bidding trading manner, accounting for 1.47% of the total share capital of the company, with a shareholding amount of approximately RMB 30.0645 million.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) plans to distribute CNY 0.1 per 10 shares in 2023 with ex-rights and ex-dividend on July 26.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) announced that it plans to distribute cash to all shareholders for every 10 shares in 2023...
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ): Terminates restructuring matters.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) announced that it will hold the thirteenth director's meeting on July 10, 2024, according to the company's announcement...
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) has not yet engaged in synthetic biology business.
On June 21, Gelunhui reported that Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ) stated on the investor interactive platform that synthetic biology is a national strategic industry with green and low-carbon features. However, the subsidiaries within the scope of consolidation of the company have not engaged in synthetic biology business.
Chengdu Huasun Technology Group Inc., Ltd. (000790.SZ): Huang Mingliang resigned as CEO and was succeeded by Song Tao.
On June 18th, Gelunhui announced that Chengdu Huasun Technology Group Inc., Ltd.'s board of directors recently received the resignation report of the company's president, Mr. Huang Mingliang, in the form of a written submission. After resigning as president, Mr. Huang Mingliang will continue to serve as the chairman of the board of directors, as well as other relevant positions under the board of directors' specialized committee, to enable strategic planning and business management integration for the company. As of the announcement disclosure date, Mr. Huang Mingliang did not directly hold any company shares. On June 18, 2024, the Thirteenth Board of Directors' Thirteenth Conference of the company approved the Appointment Proposal for the company's President, and Mr. Song Tao was appointed as the company's President.
BT Financial Report Instant Analysis: Chengdu Huasun Technology Group Inc., Ltd.'s Q1 2024: Challenges and Opportunities in Steady Development.
Chengdu Huasun Technology Group Inc., Ltd. (stock code: 000790) is a company that focuses on the pharmaceutical and health industry, dedicating itself to achieving technological innovation and international development within the industry. Despite facing multiple challenges such as the expansion of national and local alliance procurement, fierce market competition, decrease in drug prices, and rise in raw material prices in the pharmaceutical industry in 2023, Chengdu Huasun Technology performed well in the Chinese patent medicine and traditional Chinese medicine decoction piece fields. The income and profits of these sub-industries both achieved year-on-year growth, demonstrating the company's competitive advantage in specific areas. At the policy level, the country has issued a series of policy documents to support the development of the pharmaceutical and health industry, including "the 14th Five-Year Plan."
No Data